"The U.S. Food and Drug Administration today approved Clinolipid (lipid injectable emulsion, USP) for intravenous feeding (parenteral nutrition) in adult patients, providing a source of calories and essential fatty acids for adult patients who are"...
FEIBA VH (AICC), Vapor Heated, is made from human plasma. Products made from plasma may contain infectious agents, such as viruses, that can cause disease. The risk that such products will transmit an infectious agent has been reduced by effective donor screening, testing for the presence of certain current virus infections, by inactivating and/or removing certain viruses. Despite these measures, such products can still potentially transmit disease. Because this product is made from human blood, it may carry a risk of transmitting infectious agents, e.g. viruses, and theoretically the Creutzfeldt-Jacob disease (CJD) agent. ALL infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other health care provider to Baxter Healthcare Corporation, at 1-800-423-2862 (in the U.S.). The physician should discuss the risks and benefits of this product with the patient.
FEIBA VH (AICC), Vapor Heated must be used only in patients with circulating inhibitors to one or more coagulation factors and should not be used for the treatment of bleeding episodes resulting from coagulation factor deficiencies. It should not be given to patients with significant signs of disseminated intravascular coagulation (DIC) or fibrinolysis.
Thromboembolic events may occur in the course of treatment with preparations containing the prothrombin complex, particularly following the administration of high doses and/or in patients with thrombotic risk factors.
Infusion of FEIBA VH (AICC) should not exceed single dosage of 100 units per kg of body weight and daily doses of 200 units per kg of body weight. Patients receiving more than 100 units per kg of body weight of FEIBA VH (AICC) must be monitored for the development of DIC and/or symptoms of acute coronary ischemia (see ADVERSE REACTIONS section).
High doses of FEIBA VH (AICC) should be given only as long as absolutely necessary to stop bleeding.
It has been reported that FEIBA VH (AICC) and antifibrinolytics have been given simultaneously without complications. It is recommended not to use antifibrinolytics until 12 hours after the administration of FEIBA VH (AICC).
Individuals who receive infusions of blood or plasma products may develop signs and/or symptoms of some viral infections, particularly non A, non B hepatitis.
Monitoring of Therapy
If clinical signs of intravascular coagulation occur, which include changes in blood pressure, changes in pulse rate, respiratory distress, chest pain and/or cough, the infusion should be stopped promptly and appropriate diagnostic and therapeutic measures are to be initiated.
Laboratory indications of DIC are decreased fibrinogen, decreased platelet count, and/or presence of fibrin-fibrinogen degradation products (FDP). Other indications of DIC include significantly prolonged thrombin time, prothrombin time, or partial thromboplastin time.
Non-hemophilic patients with acquired inhibitors against Factors VIII, IX or XII may have both a bleeding tendency and an increased risk of thrombosis at the same time.
Laboratory Tests and Clinical Efficacy
Tests used to control efficacy such as APTT, WBCT, and TEG do not correlate with clinical improvement. For this reason, attempts at normalizing these values by increasing the dose of FEIBA VH (AICC), Vapor Heated may not be successful and are strongly discouraged because of the potential hazard of producing DIC by overdose.
Pregnancy Category C
Animal reproduction studies have not been conducted with FEIBA VH (AICC). It is also not known whether FEIBA VH (AICC) can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. FEIBA VH (AICC) should be given to a pregnant woman only if clearly needed.
No data are available regarding the use of FEIBA VH (AICC) in newborns.
Last reviewed on RxList: 10/7/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Feiba Vh Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.